pISSN 1738-6586   eISSN 2005-5013
Open Access, Peer-reviewed
    J Clin Neurol. 2011 Mar;7(1):1-9. English.
    Published online Mar 31, 2011.
    https://doi.org/10.3988/jcn.2011.7.1.1
    Copyright © 2011 Korean Neurological Association
    Review

    Cerebral Amyloid Angiopathy: A Systematic Review

    Alessandro Biffi,a,b,c and Steven M. Greenbergb,c
      • aCenter for Human Genetic Research, Massachusetts General Hospital, Boston MA, USA.
      • bDepartment of Neurology, Massachusetts General Hospital, Boston MA, USA.
      • cProgram in Medical and Population Genetics, Broad Institute, Cambridge, MA, USA.
    • Correspondence: Alessandro Biffi, MD. Hemorrhagic Stroke Research Group and Center for Human Genetics Research, Department of Neurology, Massachusetts General Hospital, 185 Cambridge Street, CPZN 6818, Boston, MA 02114, USA. Tel +1-617-643-3304, Fax +1-617-643-3293, Email: abiffi@partners.org
    Received September 02, 2010; Revised September 17, 2010; Accepted September 17, 2010.

    This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

    Abstract

    Cerebral amyloid angiopathy (CAA) is a disorder characterized by amyloid deposition in the walls of leptomeningeal and cortical arteries, arterioles, and less often capillaries and veins of the central nervous system. CAA occurs mostly as a sporadic condition in the elderly, its incidence associating with advancing age. All sporadic CAA cases are due to deposition of amyloid-β, originating from proteolytic cleavage of the Amyloid Precursor Protein. Hereditary forms of CAA are generally familial (and therefore rare in the general population), more severe and earlier in onset. CAA-related lobar intracerebral hemorrhage is the most well-studied clinical condition associated with brain amyloid deposition. Despite ever increasing understanding of CAA pathogenesis and availability of reliable clinical and diagnostic tools, preventive and therapeutic options remain very limited. Further research efforts are required in order to identify biological targets for novel CAA treatment strategies. We present a systematic review of existing evidence regarding the epidemiology, genetics, pathogenesis, diagnosis and clinical management of CAA.

    Keywords
    cerebral amyloid angiopathy; cerebral hemorrhage; dementia

    Introduction

    The term cerebral amyloid angiopathy (CAA) describes an heterogeneous group of biochemically and genetically diverse central nervous system (CNS) disorders. All these medical conditions share a characteristic morphological finding on pathological examination, i.e. amyloid fibrils deposited in the walls of small to medium-sized, blood vessels mostly arterial. In some instances amyloid deposits have been also observed in the capillaries of CNS parenchyma and of the leptomeninges. CAA mostly occurs in the sporadic form in the elderly, while rare familial forms occur in younger patients and are generally lead to more severe clinical manifestations. While more than 25 human proteins or have been found to form amyloid fibrils in vivo, only 7 have been described in CNS disorders,1, 2 and all sporadic forms and most hereditary forms of CAA affecting the human brain are of the Aβ type (Aβ-CAA)(Table 1). In Aβ-CAA the action of β- and γ-secretases on the amyloid precursor protein (APP) lead to deposition of amyloid-β (Aβ) peptide, mirroring some aspect of Alzheimer's disease (AD) patophysiology.3

    Table 1
    Sporadic and familial (hereditary) CAA forms

    In this review we will present a summary of existing evidence regarding the epidemiology, genetics and pathogenesis of CAA, provide an overview of diagnostic tools available to clinical neurologists, as well as summarize current guidelines and recommendation for prevention and treatment of CAA-intracerebral hemorrhage (ICH)(See Appendix for literature Search criteria).

    Historical Perspective

    Vascular β-amyloid deposition in the central nervous system was first described by Gustav Oppenheim in 1909. Oppenheim found foci of necrosis in the brain parenchyma adjacent to hyalinized capillary walls in 6 of 14 brains of autopsied individuals with senile dementia and the pathological changes of AD.4 In 1938, Scholz published the first article focusing solely on cerebral vascular abnormalities now recognized as CAA.5 The observation that CAA is limited to the vascular media without adjacent parenchymal involvement was made in 1954 by Stefanos Pantelakis.6 He also described many of the hallmark pathological features of CAA: 1) preferential involvement of the small arteries and capillaries of the meninges, cerebral cortex, and cerebellar cortex; 2) topographical distribution favoring the posterior brain regions; 3) lack of staining of vessels in the white matter; 4) association with increased age and dementia; 5) lack of association with hypertension and arteriosclerosis; 6) lack of association with amyloidosis of the other organs. Over the following 20 years multiple case reports and small series suggested an association between CAA and lobar ICH. Okazaki and colleagues published a seminal article in 1979, clarifying the relationship between CAA and lobar ICH.7 They identified 23 consecutive cases of moderate to severe CAA from autopsies at Mayo Clinic (Rochester, MN). A history of lobar, multiple hemorrhages was very common in these patients. Fibrinoid degeneration of the vessel walls with microaneurysm formation was sometimes seen, as well as a double-barreled vessel wall appearance caused by cracking of the arterial media. Based on these findings, the authors concluded that CAA was an under-recognized cause of lobar ICH in the elderly, thus providing the foundation for further exploration of CAA and CAA-related lobar ICH (CAA-ICH).

    Sporadic Cerebral Amyloid Angiopathy

    As previously mentioned (Table 1), sporadic CAA mostly occurs in the elderly because of Aβ deposition (Aβ-CAA). Aβ is a normally secreted, -4 kDa, 40 or 42 amino acids in length, proteolytic product of the 677-770 amino acid type 1 integral membrane protein referred to as the Aβ precursor protein (AβPP, or more commonly APP) encoded by the APP gene on chromosome 21.8-11 Generation of Aβ from APP requires two proteolytic events, a proteolytic cleavage at the amino terminus of the Aβ sequence referred to as β-secretase and a cleavage at the carboxyl terminus known as γ-secretase.

    Epidemiology

    CAA is a frequent pathological finding and a fairly common clinical entity in the elderly. As a detectable pathology (regardless of severity), cerebrovascular amyloid is present in approximately 10% to 40% of elderly brains and 80% or more in brains with concomitant AD.12 Even when taking only relatively advanced amyloid pathology in consideration, CAA remains a frequent finding. CAA pathology graded as moderate or severe (see below for pathology grading scores) was estimated to be present in 2.3% of 65 to 74 year olds, 8.0% in 75 to 84 year olds, and 12.1% in those over 85 years in analyses of brains from the Harvard Brain Tissue Resource Center. Of note, these figures were corrected for over-representation of AD referrals.13 An even higher estimate of 21% for the prevalence of CAA graded as severe emerged from other analyses of autopsied individuals aged 85 to 86.14 The role of CAA in cerebrovascular epidemiology is of course mostly related to the increased risk for lobar ICH. Indeed, estimates for the proportion of spontaneous hemorrhages in the elderly attributable to CAA range from 10% to 20% in autopsy series to 34% in clinical series.12, 15

    Pathogenesis

    The 40-amino-acid-long Aβ (Aβ 1-40) is more soluble than the longer Aβ 1-42 and the two molecules differ in the distribution in brain and vessel walls. Aβ 1-40 tends to be the major form in the amyloid in artery walls in CAA, whereas Aβ1-42 is more prominent in the plaques in brain tissue.16, 17 It is generally accepted that conformational transitions occurring in native soluble amyloid molecules increase their content in β-sheet structures, thus favoring the formation and deposition of more insoluble oligomeric structures. In turn, these deposits trigger a secondary cascade of events including, among others, release of inflammatory components, activation of the complement system, oxidative stress, alteration of the blood-brain barrier (BBB) permeability, and cell toxicity.18, 19

    While both deposited and soluble Aβ molecules are identical in their primary structure, they exhibit completely different solubility and tinctorial properties. Soluble Aβ forms undergo a change in conformation (via mechanisms that remains largely unknown) resulting in a predominantly β-sheet structure, highly prone to oligomerization, fibrillization and deposition. The identification of soluble Aβ species in the systemic circulation, brain interstitial fluid and CSF, together with the ability of the BBB to regulate Aβ transport in both directions, originally suggested plasma Aβ to be a potential precursor of deposited amyloid.20 However, lack of brain lesions in transgenic models exhibiting several fold increased in plasma soluble Aβ strongly argues against the sole contribution of circulating species to brain deposition.21

    Since smooth muscle cells, pericytes and endothelial cells all express APP22 and isolated cerebral microvessels and meningeal blood vessels are able to produce Aβ23 the cerebral vasculature itself was therefore proposed as a possible source of cerebral Aβ. Nevertheless, the sole contribution of smooth-muscle cells to Aβ-CAA is made less likely by the existence of amyloid deposits in capillaries (which are devoid of smooth muscle) in CAA patients. In recent years, the hypothesis of a neuronal origin of Aβ and other amyloid proteins has therefore been gathering support.22, 25-27 It has been proposed that amyloid produced by neurons is drained along the perivascular interstitial fluid pathways of the brain parenchyma and leptomeninges, depositing along the vessels under specific pathologic conditions.28, 29

    Since no evidence of increased Aβ production has been found in sporadic CAA, imbalance between Aβ production and clearance is generally considered a key element in the formation of amyloid deposits. The amphyphilic nature of Aβ precludes its crossing through the BBB unless mediated by specialized carriers and/or receptor transport mechanisms. These mechanisms control the uptake of circulating Aβ into the brain30-36 and regulate clearance.37-43 Among receptors involved, Receptor for Advance Glycation End-products actively participates in brain uptake of free Aβ at the vessel wall level.30 Other receptors are more relevant for the transport of Aβ complexed with other molecules: LRP-1 mediates transcytosis of Aβ-ApoE complexes contributing to rapid CNS clearance,41 whereas megalin mediates in the cellular uptake and transport of Aβ-ApoJ.36

    The hypothesis of defective Aβ degradation, while less extensively studied as a possible mechanism for amyloid accumulation, should not be overlooked. Neprilysin, endothelin-converting enzyme, insulin-degrading enzyme, beta-amyloid-converting enzyme 1, plasmin and matrix metalloproteases are among the major enzymes known to participate in brain Aβ catabolic pathways.44-46 Reduced levels and/or activity of Aβ degrading enzymes favor Aβ accumulation, as documented in murine models, in which gene deletion of different proteases translate into increased levels of Aβ deposition.45, 46

    Genetics of sporadic CAA

    The ApoE ε4 and ε2 alleles are the only genetic risk factors robustly associated with risk of developing sporadic Aβ-CAA.47 Interestingly ApoE ε2, which exerts a protective effect on AD risk, increases risk of ICH in Aβ-CAA patients.48, 49 ApoE interacts with soluble and aggregated Aβ in vitro and in vivo and is therefore likely to be involved in both parenchymal and vascular amyloidosis.50-53 Further studies tested the role of human ApoE alleles on the formation of parenchymal and vascular amyloid. The presence of the ε4 allele led to substantial Aβ-CAA with only few parenchymal amyloid deposits. The ε3 allele, however, resulted in almost no vascular and parenchymal amyloidosis.54 In young mice, an increased ratio of Aβ 40 : 42 was observed in brain extracellular pools and a lower Aβ 40 : 42 ratio in CSF, suggesting that ApoE ε4 causes altered clearance and transport of Aβ within different brain compartments. These findings highlight again the importance of a high Aβ 40 : 42 ratio for the formation of vascular amyloid. Other genetic risk factors for Aβ-CAA have been investigated, but their role remains unclear, thus requiring additional research efforts.

    Neuropathology

    Characteristic findings

    In hematoxylin-eosin stained sections severe CAA can be recognized by acellular thickening of blood vessel walls, but this finding is non-specific for CAA since it occurs in a variety of other disorders, including hypertensive angiopathy.55 In CAA, Aβ is deposited mainly as amyloid-β fibrils in close contact with smooth muscle cells.56, 57 Non-fibrillar, monomeric and oligomeric Aβ was also demonstrated inside smooth muscle cells.56 Depending on the severity of CAA, Aβ depositions have been shown primarily in the abluminal portion of the tunica media, often surrounding smooth muscle cells, and in the adventitia. With increasing severity, Aβ infiltrates all layers of the vessel wall, which shows loss of smooth muscle cells. Finally, the vascular architecture is severely disrupted and "double barreling", microaneurysm formation, fibrinoid necrosis, and evidence of perivascular leakage may be seen.58 Even in very high degrees of CAA-related changes, endothelial cells are well preserved and usually not affected. Perivascular hemorrhages are frequent around blood vessels affected with CAA.

    Several authors also reported CAA-associated inflammation/vasculitis.59, 60 Two subtypes of CAA-associated inflammation have been described so far: a non-vasculitic form called perivascular infiltration, which is characterized by perivascular infiltration of the parenchyma by multinucleated giant cells and a vasculitic form called transmural granulomatous angiitis, which is characterized by inflammation of the vessel wall with the occasional presence of granulomas. Both pathologic forms can co-occur, suggesting at least a partial overlap in biological mechanisms.

    Topographical distribution

    CAA distribution is characteristically patchy and segmental. In one given histological slide there may be foci showing vessels with varying degrees of amyloid depositions adjacent to foci showing vessels without any amyloid deposition. This phenomenon might lead to an under-diagnosis of CAA in postmortem examination, as even in severe cases a given histological slide might not contain amyloid-laden blood vessels. It has been shown by many authors that CAA is most frequent in the occipital lobe, followed by either frontal, temporal or parietal lobes, respectively. Furthermore, the occipital lobe is not only the site most frequently affected with CAA but also most severely so. CAA is more rarely seen in the basal ganglia, thalamus, and cerebellum, while both white matter and brainstem are usually spared.61-63

    Histological diagnosis

    Histological diagnosis of CAA requires use of special staining for amyloid under light microscopy. Puchtler alkaline Congo-red stain has been the standard method of amyloid staining for a long time, but since this stain is relatively unstable and has low sensitivity, a control staining with positive specimens is absolutely essential.64 Daylon stain (also known as direct fast scarlet) is more sensitive: it is therefore of greater utility in detecting smaller amounts of amyloid deposition, but requires more careful observation because of a known tendency to overstain.64 Fluorescent microscopy is also useful for the diagnosis of amyloidosis. Thioflavin-S is a sensitive stain for amyloid deposition, and it has been used from long time along with Congo-red staining.65 Immunohistochemistry with fluorescent antibodies specific for precursor proteins is also a reliable diagnostic complement.

    CAA severity grading

    Two grading systems for CAA are commonly used in routine neuropathology. Olichney et al.66 proposed the scale: 0, no Aβ positive blood vessels; 1, scattered Aβ positivity in either leptomeningeal or intracortical blood vessels; 2, strong, circumferential Aβ positivity in either some leptomeningeal or intracortical blood vessels; 3, widespread, strong, circumferential Aβ positivity in leptomeningeal and intracortical blood vessels; 4, same as 3 with additional dyshoric changes. Vonsattel et al.67 graded CAA with respect to the severity of pathological changes in a given blood vessel: mild, amyloid is restricted to the tunica media without significant destruction of smooth muscle cells; moderate, the tunica media is replaced by amyloid and is thicker than normal; severe, extensive amyloid deposition with focal wall fragmentation or even double barreling of the vessel wall, microaneurysm formation, fibrinoid necrosis, and leakage of blood through the blood vessel wall.

    Clinical features

    CAA can be completely asymptomatic, especially since approximately 50% of individuals over 80 years of age display some pathology evidence of amyloid deposition as part of normal aging processes. However, amyloid deposition in cerebral blood vessels does favor development of several clinical conditions. Amyloid deposition can weaken cerebral blood vessels walls, causing rupture and therefore leading to both asymptomatic microbleeds and lobar ICH. Amyloid deposits can also obliterate the vessel lumen, leading to ischemia and related clinical manifestations (cerebral infarction, "incomplete infarction", leukoaraiosis). Focal neurological deficits, disturbances of consciousness, progressive cognitive decline, dementia, and death can occur as a consequence of these vascular mechanisms (albeit additional biological processes are also likely to be implicated).15

    CAA-related ICH (CAA-ICH) accounts for 5-20% of all spontaneous (non-traumatic) ICH in elderly subjects. CAA-ICH tends to be lobar in location, due to the involvement of superficial cortical and leptomeningeal vessels, and often manifests as recurrent or multiple simultaneous bleeding events, because of the widespread nature of the angiopathy. Hypertension is less commonly associated with lobar hemorrhages than with non-lobar ICH.15 Increasing evidence is emerging that CAA may be a risk factor for thrombolysis-related intracerebral hemorrhage. CAAH and thrombolysis-related intracerebral hemorrhage share some clinical features, such as predisposition to lobar or superficial regions of the brain, multiple hemorrhages, increasing frequency with age, and an association with dementia.68 In vitro work showed that accumulation of amyloid-beta peptide causes degeneration of cells in the walls of blood vessels, affects vasoactivity, and improves proteolytic mechanisms, such as fibrinolysis, anticoagulation, and degradation of the extracellular matrix.68

    Clinical diagnosis

    While hemorrhagic stroke is the defining clinical characteristic raising concern for CAA, there are no pathognomonic clinical features of CAA-ICH. Headache, focal neurological deficits, seizures and altered level of consciousness occur in all ICH patients, based on hematoma size and location rather than pathophysiological mechanisms. Spontaneous bleeding due to CAA, as previously mentioned, can also be small and asymptomatic and is commonly referred to as a "microbleed".69, 70 Microbleeds are part of the integrated clinical and imaging assessment leading to CAA diagnosis during life (see below), and have also been shown to correlate with risk of cognitive decline, functional dependence and lobar ICH recurrence.71 A recent study, based on assessment of microbleeds and leukoaraiosis in CAA-ICH and hypertensive ICH patients, suggested that both pathophysiological mechanisms might be present simultaneously in up to 25% of ICH patients.72

    A definitive CAA diagnosis can only be formulated after histological investigation of affected brain tissue, obtained at autopsy or via brain biopsy. In practice evidence of CAA is very often found unexpectedly at post-mortem investigation. Non-invasive CAA diagnostic criteria have been therefore developed and refined in the past decade, in order to both improve and standardize diagnosis during life (Table 2).73 Additional refinement of these criteria based on inclusion of superficial siderosis among imaging markers of CAA has been recently proposed.74 Furthermore, positron emission tomography imaging with the beta-amyloid-binding compound Pittsburgh Compound B has been recently proposed as a potential noninvasive method for CAA detection in living subjects.75 A recent report suggested that severity of Pittsburgh Compound B retention is associated with risk of recombinant tissue-type plasminogen activator-associated intraparenchymal hemorrhage.76

    Table 2
    Boston criteria for CAA diagnosis

    Prevention and treatment

    No evidence-based treatment or preventive strategy for CAA or CAA-ICH exists at this time. Corticosteroid treatment has been shown in some case reports and small series to ameliorate symptoms associated with CAA-related inflammation, possibly by reducing vasogenic edema.77 Other immunosuppressant treatments have been reported to influence the course of inflammatory CAA, but available evidence is extremely limited.78 However, recently reported results from the PROGRESS trial suggests that blood pressure control is likely to reduce risk of CAA-ICH recurrence.79 While CAA has been shown to represent a risk factor for thrombolysis-associated ICH and warfarin-related hemorrhagic stroke, no clear tools for risk prediction and stratification have yet been developed and validated. In particular, there is growing interest in the possible role of leukoaraiosis and microbleeds as surrogate markers for CAA severity, and therefore as possible tools for prediction of CAA-ICH.80 Of note, a recent study found an association between aspirin use and CAA-ICH recurrence, providing preliminary evidence of a possible association between microbleed burden and re-bleeding risk due to antiplatelet treatment.81 Similarly, in light of recent evidence associating statin treatment with increased risk for ICH recurrence additional research is necessary in order to determine the risks and benefits of lipid-loweirng treatment for CAA patients.82

    Hereditary Cerebral Amyloid Angiopathy

    Overall, hereditary forms of CAA (Table 1) are generally more severe than sporadic forms and often characterized by earlier age of onset, more severe clinical course, and earlier age of neurologic devastation and/or death.83-89 Unlike sporadic CAA, hereditary forms are exceedingly rare and tend to present in selected families in the form of autosomal dominant disorders. Both sporadic and hereditary CAA often cause cognitive impairment, but lobar ICH is not a consistent feature of all hereditary CAA forms. Specifically, hereditary CAA can be further classified in Aβ and non-Aβ forms, based on the accumulating peptide (or fragment). While involvement of leptomeningeal or cerebral vessels has been described in all familial syndromes, lobar ICH rarely dominates the clinical picture of non-Aβ CAA, with the remarkable exception of the non-Aβ Icelandic type. As for familial Aβ forms (Fig. 1), although some alterations in APP processing have been associated with corresponding mutations (particularly the Flemish mutation), their primary characteristic appears to be a modification of biochemical and cell biological properties of the peptide itself, including conformation, aggregation and fibril generation. Of note, APOE seems to play less of a significant role in hereditary than sporadic CAA, possibly reflecting the overriding role of the autosomal dominant Aβ mutation in determining Amyloid accumulation and therefore disease risk and clinical course.

    Fig. 1
    Mutations in the APP gene and their relationship to the amino acid sequence of the Aβ peptide. APP: amyloid precursor protein.

    Conclusion

    CAA presents in both sporadic and hereditary familial forms. While hereditary forms are rare in the population and tend to affect younger individuals, sporadic CAA is a common disease of the elderly, its incidence and severity increasing with age. The emphasis placed on CAA in medical practice and research is justified by its association with cognitive decline, dementia and, more importantly, spontaneous lobar ICH. In the past decade a vast body of knowledge has been gathered on CAA pathogenesis, and efficient clinical and imaging tools have been developed to allow reliable diagnosis in life. However, further research efforts are required in order to identify targets for therapeutic and preventive interventions, aimed at limiting mortality, disability and neurological compromise associated with this CAA and CAA-related ICH.

    Notes

    The authors have no financial conflicts of interest.

    References

      1. Revesz T, Ghiso J, Lashley T, Plant G, Rostagno A, Frangione B, et al. Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view. J Neuropathol Exp Neurol 2003;62:885–898.
      1. Frangione B, Révész T, Vidal R, Holton J, Lashley T, Houlden H, et al. Familial cerebral amyloid angiopathy related to stroke and dementia. Amyloid 2001;8 Suppl 1:36–42.
      1. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001;81:741–766.
      1. Oppenheim G. Über "drusige Nekrosen" in der Grosshirnrinde. Neurol Centralbl 1909;28:410–413.
      1. Scholz WZ. StudienzurpathologiederhirngefabeII: die drusige entartung der hirnarterien und capillaren. Gesamte Neurol Psychiatr 1938;162:694–715.
      1. Pantelakis S. [A particular type of senile angiopathy of the central nervous system: congophilic angiopathy, topography and frequency]. Monatsschr Psychiatr Neurol 1954;128:219–256.
      1. Okazaki H, Reagan TJ, Campbell RJ. Clinicopathologic studies of primary cerebral amyloid angiopathy. Mayo Clin Proc 1979;54:22–31.
      1. Goldgaber D, Lerman MI, McBride OW, Saffiotti U, Gajdusek DC. Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. Science 1987;235:877–880.
      1. Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 1992;359:322–325.
      1. Robakis NK, Ramakrishna N, Wolfe G, Wisniewski HM. Molecular cloning and characterization of a cDNA encoding the cerebrovascular and the neuritic plaque amyloid peptides. Proc Natl Acad Sci U S A 1987;84:4190–4194.
      1. Busciglio J, Gabuzda DH, Matsudaira P, Yankner BA. Generation of beta-amyloid in the secretory pathway in neuronal and nonneuronal cells. Proc Natl Acad Sci U S A 1993;90:2092–2096.
      1. Jellinger KA. Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm 2002;109:813–836.
      1. Greenberg SM, Vonsattel JP. Diagnosis of cerebral amyloid angiopathy. Sensitivity and specificity of cortical biopsy. Stroke 1997;28:1418–1422.
      1. Neuropathology Group; Medical Research Council Cognitive Function and Aging Study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 2001;357:169–175.
      1. Greenberg SM. In: Stroke: Pathophysiology, Diagnosis and Management. New York: Harcourt Inc.; 2004. pp. 693-697.
      1. Ishii K, Tamaoka A, Mizusawa H, Shoji S, Ohtake T, Fraser PE, et al. Abeta1-40 but not Abeta1-42 levels in cortex correlate with apolipoprotein E epsilon4 allele dosage in sporadic Alzheimer's disease. Brain Res 1997;748:250–252.
      1. Harper JD, Lieber CM, Lansbury PT Jr. Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-beta protein. Chem Biol 1997;4:951–959.
      1. Ghiso J, Rostagno A, Tomidokoro Y, Lashley T, Bojsen-Møller M, Braendgaard H, et al. Genetic alterations of the BRI2 gene: familial British and Danish dementias. Brain Pathol 2006;16:71–79.
      1. Rostagno A, Lal R, Ghiso J. Protein misfolding, aggregation, and fibril formation: common features of cerebral and non-cerebral amyloid diseases. In: Dawbarn D, Allen S, editors. The neurobiology of Alzheimer's disease. Oxford: Oxford University Press; 2007. pp. 133-160.
      1. Zlokovic BV. Vascular disorder in Alzheimer's disease: role in pathogenesis of dementia and therapeutic targets. Adv Drug Deliv Rev 2002;54:1553–1559.
      1. Kawarabayashi T, Shoji M, Sato M, Sasaki A, Ho L, Eckman CB, et al. Accumulation of beta-amyloid fibrils in pancreas of transgenic mice. Neurobiol Aging 1996;17:215–222.
      1. Burgermeister P, Calhoun ME, Winkler DT, Jucker M. Mechanisms of cerebrovascular amyloid deposition. Lessons from mouse models. Ann N Y Acad Sci 2000;903:307–316.
      1. Kalaria RN, Premkumar DR, Pax AB, Cohen DL, Lieberburg I. Production and increased detection of amyloid beta protein and amyloidogenic fragments in brain microvessels, meningeal vessels and choroid plexus in Alzheimer's disease. Brain Res Mol Brain Res 1996;35:58–68.
      1. Chesebro B, Trifilo M, Race R, Meade-White K, Teng C, LaCasse R, et al. Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science 2005;308:1435–1439.
      1. Herzig MC, Winkler DT, Burgermeister P, Pfeifer M, Kohler E, Schmidt SD, et al. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci 2004;7:954–960.
      1. Van Dorpe J, Smeijers L, Dewachter I, Nuyens D, Spittaels K, Van Den Haute C, et al. Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the london mutant of human APP in neurons. Am J Pathol 2000;157:1283–1298.
      1. Vidal R, Barbeito AG, Miravalle L, Ghetti B. Cerebral amyloid angiopathy and parenchymal amyloid deposition in transgenic mice expressing the Danish mutant form of human BRI2. Brain Pathol 2009;19:58–68.
      1. Weller RO, Massey A, Newman TA, Hutchings M, Kuo YM, Roher AE. Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. Am J Pathol 1998;153:725–733.
      1. Weller RO, Subash M, Preston SD, Mazanti I, Carare RO. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol 2008;18:253–266.
      1. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003;9:907–913.
      1. Ghilardi JR, Catton M, Stimson ER, Rogers S, Walker LC, Maggio JE, et al. Intra-arterial infusion of [125I] A beta 1-40 labels amyloid deposits in the aged primate brain in vivo. Neuroreport 1996;7:2607–2611.
      1. Mackic JB, Weiss MH, Miao W, Kirkman E, Ghiso J, Calero M, et al. Cerebrovascular accumulation and increased blood-brain barrier permeability to circulating Alzheimer's amyloid beta peptide in aged squirrel monkey with cerebral amyloid angiopathy. J Neurochem 1998;70:210–215.
      1. Maness LM, Banks WA, Podlisny MB, Selkoe DJ, Kastin AJ. Passage of human amyloid beta-protein 1-40 across the murine blood-brain barrier. Life Sci 1994;55:1643–1650.
      1. Martel CL, Mackic JB, Matsubara E, Governale S, Miguel C, Miao W, et al. Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer's amyloid beta. J Neurochem 1997;69:1995–2004.
      1. Poduslo JF, Curran GL, Sanyal B, Selkoe DJ. Receptor-mediated transport of human amyloid beta-protein 1-40 and 1-42 at the blood-brain barrier. Neurobiol Dis 1999;6:190–199.
      1. Zlokovic BV, Martel CL, Matsubara E, McComb JG, Zheng G, McCluskey RT, et al. Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proc Natl Acad Sci U S A 1996;93:4229–4234.
      1. Bading JR, Yamada S, Mackic JB, Kirkman L, Miller C, Calero M, et al. Brain clearance of Alzheimer's amyloid-beta40 in the squirrel monkey: a SPECT study in a primate model of cerebral amyloid angiopathy. J Drug Target 2002;10:359–368.
      1. DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 2002;295:2264–2267.
      1. Ghersi-Egea JF, Gorevic PD, Ghiso J, Frangione B, Patlak CS, Fenstermacher JD. Fate of cerebrospinal fluid-borne amyloid beta-peptide: rapid clearance into blood and appreciable accumulation by cerebral arteries. J Neurochem 1996;67:880–883.
      1. Monro OR, Mackic JB, Yamada S, Segal MB, Ghiso J, Maurer C, et al. Substitution at codon 22 reduces clearance of Alzheimer's amyloid-beta peptide from the cerebrospinal fluid and prevents its transport from the central nervous system into blood. Neurobiol Aging 2002;23:405–412.
      1. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, et al. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000;106:1489–1499.
      1. Zlokovic BV, Yamada S, Holtzman D, Ghiso J, Frangione B. Clearance of amyloid beta-peptide from brain: transport or metabolism? Nat Med 2000;6:718–719.
      1. Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest 2005;115:3285–3290.
      1. Miners JS, Baig S, Palmer J, Palmer LE, Kehoe PG, Love S. Abeta-degrading enzymes in Alzheimer's disease. Brain Pathol 2008;18:240–252.
      1. Selkoe DJ. Clearing the brain's amyloid cobwebs. Neuron 2001;32:177–180.
      1. Wang YJ, Zhou HD, Zhou XF. Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives. Drug Discov Today 2006;11:931–938.
      1. Sudlow C, Martínez González NA, Kim J, Clark C. Does apolipoprotein E genotype influence the risk of ischemic stroke, intracerebral hemorrhage, or subarachnoid hemorrhage? Systematic review and meta-analyses of 31 studies among 5961 cases and 17,965 controls. Stroke 2006;37:364–370.
      1. Nicoll JA, Burnett C, Love S, Graham DI, Dewar D, Ironside JW, et al. High frequency of apolipoprotein E epsilon 2 allele in hemorrhage due to cerebral amyloid angiopathy. Ann Neurol 1997;41:716–721.
      1. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997;278:1349–1356.
      1. Wisniewski T, Golabek A, Matsubara E, Ghiso J, Frangione B. Apolipoprotein E: binding to soluble Alzheimer's beta-amyloid. Biochem Biophys Res Commun 1993;192:359–365.
      1. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 1993;90:1977–1981.
      1. Russo C, Angelini G, Dapino D, Piccini A, Piombo G, Schettini G, et al. Opposite roles of apolipoprotein E in normal brains and in Alzheimer's disease. Proc Natl Acad Sci U S A 1998;95:15598–15602.
      1. Wisniewski T, Lalowski M, Golabek A, Vogel T, Frangione B. Is Alzheimer's disease an apolipoprotein E amyloidosis? Lancet 1995;345:956–958.
      1. Holtzman DM. Role of apoe/Abeta interactions in the pathogenesis of Alzheimer's disease and cerebral amyloid angiopathy. J Mol Neurosci 2001;17:147–155.
      1. Graham DI, Lantos PL. In: Greenfield's Neuropathology. London: Arnold; 2002. pp. 293-296.
      1. Frackowiak J, Zoltowska A, Wisniewski HM. Non-fibrillar beta-amyloid protein is associated with smooth muscle cells of vessel walls in Alzheimer disease. J Neuropathol Exp Neurol 1994;53:637–645.
      1. Wisniewski HM, Wegiel J, Vorbrodt AW, Mazur-Kolecka B, Frackowiak J. Role of perivascular cells and myocytes in vascular amyloidosis. Ann N Y Acad Sci 2000;903:6–18.
      1. Revesz T, Holton JL, Lashley T, Plant G, Rostagno A, Ghiso J, et al. Sporadic and familial cerebral amyloid angiopathies. Brain Pathol 2002;12:343–357.
      1. Eng JA, Frosch MP, Choi K, Rebeck GW, Greenberg SM. Clinical manifestations of cerebral amyloid angiopathy-related inflammation. Ann Neurol 2004;55:250–256.
      1. Scolding NJ, Joseph F, Kirby PA, Mazanti I, Gray F, Mikol J, et al. Abeta-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy. Brain 2005;128:500–515.
      1. Attems J, Jellinger KA, Lintner F. Alzheimer's disease pathology influences severity and topographical distribution of cerebral amyloid angiopathy. Acta Neuropathol 2005;110:222–231.
      1. Pfeifer LA, White LR, Ross GW, Petrovitch H, Launer LJ. Cerebral amyloid angiopathy and cognitive function: the HAAS autopsy study. Neurology 2002;58:1629–1634.
      1. Ellis RJ, Olichney JM, Thal LJ, Mirra SS, Morris JC, Beekly D, et al. Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Neurology 1996;46:1592–1596.
      1. Puchtler H, Waldrop FS, Meloan SN. A review of light, polarization and fluorescence microscopic methods for amyloid. Appl Pathol 1985;3:5–17.
      1. Stiller D, Katenkamp D, Thoss K. [Staining mechanism of thioflavin T with special reference to the localization of amyloid]. Acta Histochem 1972;42:234–245.
      1. Olichney JM, Hansen LA, Hofstetter CR, Grundman M, Katzman R, Thal LJ. Cerebral infarction in Alzheimer's disease is associated with severe amyloid angiopathy and hypertension. Arch Neurol 1995;52:702–708.
      1. Vonsattel JP, Myers RH, Hedley-Whyte ET, Ropper AH, Bird ED, Richardson EP Jr. Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study. Ann Neurol 1991;30:637–649.
      1. McCarron MO, Nicoll JA. Cerebral amyloid angiopathy and thrombolysis-related intracerebral haemorrhage. Lancet Neurol 2004;3:484–492.
      1. Greenberg SM, Vernooij MW, Cordonnier C, Viswanathan A, Al-Shahi Salman R, Warach S, et al. Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol 2009;8:165–174.
      1. Greenberg SM, Nandigam RN, Delgado P, Betensky RA, Rosand J, Viswanathan A, et al. Microbleeds versus macrobleeds: evidence for distinct entities. Stroke 2009;40:2382–2386.
      1. Greenberg SM, Eng JA, Ning M, Smith EE, Rosand J. Hemorrhage burden predicts recurrent intracerebral hemorrhage after lobar hemorrhage. Stroke 2004;35:1415–1420.
      1. Smith EE, Nandigam KR, Chen YW, Jeng J, Salat D, Halpin A, et al. MRI markers of small vessel disease in lobar and deep hemispheric intracerebral hemorrhage. Stroke 2010;41:1933–1938.
      1. Knudsen KA, Rosand J, Karluk D, Greenberg SM. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology 2001;56:537–539.
      1. Linn J, Halpin A, Demaerel P, Ruhland J, Giese AD, Dichgans M, et al. Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. Neurology 2010;74:1346–1350.
      1. Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 2007;62:229–234.
      1. Ly JV, Rowe CC, Villemagne VL, Zavala JA, Ma H, O'Keefe G, et al. Cerebral β-amyloid detected by Pittsburgh compound B positron emission topography predisposes to recombinant tissue plasminogen activator-related hemorrhage. Ann Neurol 2010;68:959–962.
      1. Kloppenborg RP, Richard E, Sprengers ME, Troost D, Eikelenboom P, Nederkoorn PJ. Steroid responsive encephalopathy in cerebral amyloid angiopathy: a case report and review of evidence for immunosuppressive treatment. J Neuroinflammation 2010;7:18.
      1. Luppe S, Betmouni S, Scolding N, Wilkins A. Cerebral amyloid angiopathy related vasculitis: successful treatment with azathioprine. J Neurol 2010;257:2103–2105.
      1. Arima H, Tzourio C, Anderson C, Woodward M, Bousser MG, Mac-Mahon S, et al. Effects of perindopril-based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke 2010;41:394–396.
      1. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010;9:689–701.
      1. Biffi A, Halpin A, Towfighi A, Gilson A, Busl K, Rost N, et al. Aspirin and recurrent intracerebral hemorrhage in cerebral amyloid angiopathy. Neurology 2010;75:693–698.
      1. Athyros VG, Tziomalos K, Karagiannis A, Wierzbicki AS, Mikhailidis DP. Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association? Curr Opin Cardiol 2010;25:406–410.
      1. Palsdottir A, Snorradottir AO, Thorsteinsson L. Hereditary cystatin C amyloid angiopathy: genetic, clinical, and pathological aspects. Brain Pathol 2006;16:55–59.
      1. Bornebroek M, De Jonghe C, Haan J, Kumar-Singh S, Younkin S, Roos R, et al. Hereditary cerebral hemorrhage with amyloidosis Dutch type (AbetaPP 693): decreased plasma amyloid-beta 42 concentration. Neurobiol Dis 2003;14:619–623.
      1. De Jonghe C, Zehr C, Yager D, Prada CM, Younkin S, Hendriks L, et al. Flemish and Dutch mutations in amyloid beta precursor protein have different effects on amyloid beta secretion. Neurobiol Dis 1998;5:281–286.
      1. Farzan M, Schnitzler CE, Vasilieva N, Leung D, Choe H. BACE2, a beta -secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein. Proc Natl Acad Sci U S A 2000;97:9712–9717.
      1. Haass C, Hung AY, Selkoe DJ, Teplow DB. Mutations associated with a locus for familial Alzheimer's disease result in alternative processing of amyloid beta-protein precursor. J Biol Chem 1994;269:17741–17748.
      1. Stenh C, Nilsberth C, Hammarbäck J, Engvall B, Näslund J, Lannfelt L. The Arctic mutation interferes with processing of the amyloid precursor protein. Neuroreport 2002;13:1857–1860.
      1. Van Nostrand WE, Melchor JP, Cho HS, Greenberg SM, Rebeck GW. Pathogenic effects of D23N Iowa mutant amyloid beta -protein. J Biol Chem 2001;276:32860–32866.
    Cited by
    Crossref 286
    Google Scholar 
    PubMed Central 159
    Scopus 295
    Web of Science >100
    MeSH Terms
    Aged
    Amyloid
    Arteries
    Arterioles
    Brain
    Capillaries
    Central Nervous System
    Cerebral Amyloid Angiopathy
    Cerebral Hemorrhage
    Congenital Abnormalities
    Dementia
    Ear
    Humans
    Incidence
    Plaque, Amyloid
    Veins
    Metrics
    Share
    Links to
    Figures
    slide

    1 / 1

    Tables
    slide
    slide

    1 / 2

    PERMALINK